Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: A systematic review and meta-analysis

Oncotarget

Volumn 6, Issue 36, 2015, Pages 39088-39097

  Luchini, Claudio ^a,b   Veronese, Nicola ^c   Solmi, Marco ^c   Cho, Hanbyoul ^d   Kim, Jae Hoon ^d   Chou, Angela ^e,f,g   Gill, Anthony J ^e,f   Faraj, Sheila F ^b   Chaux, Alcides ^b,h   Netto, George J ^b   Nakayama, Kentaro ⁱ   Kyo, Satoru ⁱ   Lee, Soo Young ^j   Kim, Duck Woo ^k   Yousef, George M ^l   Scorilas, Andreas ^m   Nelson, Gregg S ⁿ   Köbel, Martin ^o   Kalloger, Steve E ^p   Schaeffer, David F ^p   Yan, Hai Bo ^q   Liu, Feng ^q   Yokoyama, Yoshihito ^r   Zhang, Xianyu ^s   Pang, Da ^s   Lichner, Zsuzsanna ^l   Sergi, Giuseppe ^c   Manzato, Enzo ^c   Capelli, Paola ^a   Wood, Laura D ^b   Scarpa, Aldo ^a   Correll, Christoph U ^t,u,v,w   more..

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d Yonsei University College of Medicine   (South Korea)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h CENTRO PARA EL DESARROLLO DE LA INVESTIGACIÓN CIENTÍFICA   (Paraguay)

ⁱ SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^j Gachon University College of Medicine   (South Korea)

^k Seoul National University Bundang Hospital   (South Korea)

^l ST MICHAEL'S HOSPITAL   (Canada)

^m UNIVERSITY OF ATHENS   (Greece)

ⁿ TOM BAKER CANCER CENTRE   (Canada)

^o UNIVERSITY OF CALGARY   (Canada)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q FUDAN UNIVERSITY   (China)

^r HIROSAKI UNIVERSITY   (Japan)

^s HARBIN MEDICAL UNIVERSITY   (China)

^t ZUCKER HILLSIDE HOSPITAL   (United States)

^u DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^v FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^w ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

ARID1A; Chromatin remodeling; SWI SNF; Targeted therapy; Tumor suppressor gene

Indexed keywords

ARID1A GENE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE GENITAL TRACT CANCER; GENE FUNCTION; GENE MUTATION; GENETIC SCREENING; GEOGRAPHIC ORIGIN; HUMAN; IMMUNOHISTOCHEMISTRY; RISK; SEX DIFFERENCE; SURVIVAL RATE; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER; COHORT ANALYSIS; FEMALE; GENETICS; MALE; META ANALYSIS; MIDDLE AGED; MUTATION; NEOPLASM; PROGNOSIS;

ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

COHORT STUDIES; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84948755634     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5142     Document Type: Article

References (51)

1. Biegel JA, Busse TM, Weissman BE. SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet. 2014; 166C:350-66.
2. Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomic Inform. 2013; 11:164-173.
3. Feinberg AP. Epigenetic stochasticity, nuclear structure and cancer: the implications for medicine. J Intern Med. 2014; 276:5-11.
4. Wilson GW, Roberts CW. SWI/SNF nucleosome remodelers and cancer. Nat Rew Cancer. 2011; 11:481-492.
5. Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, Angiuoli SV, Sausen M, Kann L, Shukla M, Makar R, Wood LD, Diaz LA Jr, et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun. 2014; 5:5006.
6. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBMR1 in renal carcinoma. Nature. 2011; 469:539-542.
7. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extendive roles in human malignangcy. Nat Genet. 2013; 45:592-601.
8. Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013; 3:35-43.
9. Flores-Alcantar A, Gonzalez-Sandoval A, Escalante-Alcade D, Lomeli H. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle. Cell Tissue Res. 2011; 345:137-148.
10. Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, Wang W. A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol. 2000; 20:8879-8888.
11. Mao TL, Shih IeM. The roles of ARID1A in gynecologic cancer. J Gynecol Oncol. 2013; 24:376-381.
12. Samartzis E, Noske A, Dedes KJ, Fink D, Imesch P. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis-associated ovarian carcinomas. Int J Mol Sci. 2013; 14:18824-18849.
13. Wu RC, Wang TL, Shih IeM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014; 15:655-64.
14. Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol. 2013; 44:1365-1374.
15. Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, DeSilva K, Gill AJ. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014; 45:1697-1703.
16. Fadare O, Renshaw IL, Liang SX. Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance?. A Pilot Assessment. J Cancer. 2012; 3:129-136.
17. Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Ellis C, Driscoll T, Schoenberg MP, Bivalacqua TJ, Shih IeM, Netto GJ. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Hum Pathol. 2014; 45:2233-2239.
18. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Ishikawa M, Ishibashi T, Iida K, Otsuki Y, Nakayama S, Miyazaki K. Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix. Int J Gynecol Cancer. 2012; 22:208-212.
19. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S, Miyazaki K. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012; 25:282-288.
20. Kim MJ, Gu MJ, Chang HK, Yu E. Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma. Histopathology. 2015; 66:508-516.
21. Lee SY, Kim DW, Lee HS, Ihn MH, Oh HK, Park do J. Loss of AT-Rich Interactive Domain 1A Expression in Gastrointestinal Malignancies. Oncology. 2015; 88:234-240.
22. Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol. 2013; 182:1163-1170.
23. Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2012; 22:9-14.
24. Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, Shih IeM. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010; 11:5120-5128.
25. Nelson GS, Pink A, Lee S, Han G, Morris D, Ogilvie T, Duggan MA, Köbel M. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol. 2013; 131:309-314.
26. Numata M, Morinaga S, Watanabe T, Tamagawa H, Yamamoto N, Shiozawa M, Nakamura Y, Kameda Y, Okawa S, Rino Y, Akaike M, Masuda M, Miyagi Y. The clinical significance of SWI/SNF complex in pancreatic cancer. Int J Oncol. 2013; 42:403-410.
27. Park JH, Lee C, Suh JH, Chae JY, Kim HW, Moon KC. Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. Hum Pathol. 2015; 46:454-460.
28. Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Miyazaki K. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum Pathol. 2013; 44:103-109.
29. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011; 43:1219-1223.
30. Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One. 2012; 7:e40364.
31. Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, Wang RY, Huang YX1, Jin Y, Wang F, Qiu MZ, Luo HY, Zhang DS, et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol. 2014; 20:18404-18412.
32. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum Pathol. 2014; 45:1258-1268.
33. Yan HB, Wang XF, Zhang Q, Tang ZQ, Jiang YH, Fan HZ, Sun YH, Yang PY, Liu F. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis. 2014; 35:867-76.
34. Ye J, Zhou Y, Weiser MR, Gönen M, Zhang L, Samdani T, Bacares R, DeLair D, Ivelja S, Vakiani E, Klimstra DS, Soslow RA, Shia J. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Hum Pathol. 2014; 45:2430-2436.
35. Yokoyama Y, Matsushita Y, Shigeto T, Futagami M, Mizunuma H. Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol. 2014; 25:58-63.
36. Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji H, Ma Y, Yao G, Jiang Y, Shan M, Zhang G, Pang D. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol. 2012; 36:288-293.
37. Zhang ZM, Xiao S, Sun GY, Liu YP, Zhang FH, Yang HF, Li J, Qiu HB, Liu Y, Zhang C, Kang S, Shan BE. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. Int J Gynecol Cancer. 2014; 24:534-540.
38. Zhao J, Liu C, Zhao Z. ARID1A: a potential prognostic factor for breast cancer. Tumour Biol. 2014; 35:4813-4819.
39. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012; 25:615-624.
40. Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT. Loss of ARID1A expression and its relationship with Pi3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013; 26:1525-1535.
41. Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014; 27:255-261.
42. Streppel MM, Lata S, DelaBastide M, Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink FH, Offerhaus GJ, Antoniou E, Maitra A, McCombie WR. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene. 2014; 33:347-357.
43. Abe H, Maeda D, Hino R, Otake Y, Isogai M, Ushiku AS, Matsusaka K, Kunita A, Ushiku T, Uozaki H, Tateishi Y, Hishima T, Iwasaki Y, et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch. 2012; 461:367-377.
44. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014; 20:251-254.
45. Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V, Scarpa A. Next generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. J Clin Oncol. 2014; 32:e63-66.
46. Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P, Bencivenga M, Pecori S, Luchini C, Neves D, Turri G, Vicentini C, Montagna L, et al. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer. 2014; 17:442-449.
47. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/ oxford.htm (last access: 04/15/15).
48. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012.
49. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.
50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
51. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539-1558.